Platelet rich plasma injection for treatment of osteoarthritis

Phase 2

Completed

• Conditions: osteoarthritis; osteochondral defect; Musculoskeletal - Osteoarthritis

• Registration Number: ACTRN12611000651987
• Lead Sponsor: Kade Paterson

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2011-06-24
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

A diagnosis of OA assessed via the International Cartilage Repair Society guidelines and a visual analogue pain score of greater than 50 out of 100

Exclusion Criteria

No systemic or inflammatory joint disease, no history of crystalline or neuropathic arthropathy, no cancer or other tumour-like lesions, not pregnant or lactating, not drug abusing, no other intra articular lesion in the previous six months, no allergy to any test substance and not immunosuppressed

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Pain measured using 100mm Visual Analogue Score (VAS)[Baseline, daily for the first two weeks, weekly for the subsequent two weeks and four and eight weeks, and six and 12 months, following the final injection];Knee Injury and Osteoarthritis Outcome Score[Baseline, four and eight weeks, and six and 12 months, following the final injection]

Secondary Outcome Measures

Name	Time	Method
Maximum single leg hop for distance. Participant hops as far as possible and the distance (in cm) from the toe in starting position to heel in landing position is measured by the researcher using a tape measure. The best of three hops is recorded.[Baseline, four and eight weeks, and six and 12 months, following the final injection];Maximum number of knee bends performed in 30 seconds. Participant bends the knee without bending forward from the hip (until they cannot see a line along the toes, equivalent to about 30 degrees of knee flexion) as many times as possible in 30 seconds. Time is recorded using a stopwatch and number of bends are counted by the researcher.[Baseline, four and eight weeks, and six and 12 months, following the final injection]